前往化源商城

入驻化源商城

(rac)-Modipafant-d4

更新时间：2024-01-31 17:17:03

(rac)-Modipafant-d4结构式	常用名	(rac)-Modipafant-d4	英文名	(rac)-Modipafant-d4
	CAS号	1794707-03-1	分子量	609.11
	密度	N/A	沸点	N/A
	分子式	C₃₄H₂₅D₄ClN₆O₃	熔点	N/A
	MSDS	N/A	闪点	N/A

(rac)-Modipafant-d4用途

(rac)-Modipafant-d4(UK-74505-d4)是氘标记的(rac)-Modipafant。(Rac)-Modipafant(UK-74505)是一种口服活性、选择性、长效的不可逆血小板活化因子受体(PAFR)拮抗剂。(Rac)-莫迪帕芬预防登革热感染[1][2][3]。

英文名	(rac)-Modipafant-d4

描述	(rac)-Modipafant-d4(UK-74505-d4)是氘标记的(rac)-Modipafant。(Rac)-Modipafant(UK-74505)是一种口服活性、选择性、长效的不可逆血小板活化因子受体(PAFR)拮抗剂。(Rac)-莫迪帕芬预防登革热感染[1][2][3]。
相关类别	研究领域 >> 感染信号通路 >> 其他 >> 其他研究领域 >> 炎症/免疫
体外研究	氢、碳和其他元素的稳定重同位素已被纳入药物分子,主要作为药物开发过程中定量的示踪剂。氘化因其可能影响药物的药代动力学和代谢特征而受到关注[1]。
参考文献	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. O'Connor BJ, et al. Inhibitory effect of UK,74505, a potent and specific oral platelet activating factor (PAF) receptor antagonist, on airway and systemic responses to inhaled PAF in humans. Am J Respir Crit Care Med. 1994;150(1):35-40. [3]. Alabaster VA, et al. UK-74,505, a novel and selective PAF antagonist, exhibits potent and long lasting activity in vivo. Agents Actions Suppl. 1991;34:221-227. [4]. Parry MJ, Alabaster VA, et al. Pharmacological profile of UK-74,505, a novel and selective PAF antagonist with potent and prolonged oral activity. J Lipid Mediat Cell Signal. 1994;10(3):251-268. [5]. Souza DG, et al. Essential role of platelet-activating factor receptor in the pathogenesis of Dengue virus infection. Proc Natl Acad Sci U S A. 2009;106(33):14138-14143. [6]. Guerrero AT, et al. The role of PAF/PAFR signaling in zymosan-induced articular inflammatory hyperalgesia [published correction appears in Naunyn Schmiedebergs Arch Pharmacol. 2013 Apr;386(4):351. Zaperlon, Ana C [corrected to Zarpelon, Ana C]]. Naunyn Schmiedebergs Arch Pharmacol. 2013;386(1):51-59.

分子式	C₃₄H₂₅D₄ClN₆O₃
分子量	609.11